AFX01-13: A Phase 3, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of Peginesatide for the Correction of Anemia in Patients With Chronic Renal Failure (CRF) Not on Dialysis and Not on Erythropoiesis Stimulating Agent (ESA) Treatment
Latest Information Update: 06 Oct 2021
At a glance
- Drugs Peginesatide (Primary) ; Darbepoetin alfa
- Indications Anaemia
- Focus Therapeutic Use
- Acronyms PEARL 2
- Sponsors Affymax
- 26 May 2014 New trial record